Extrapulmonary Small Cell Carcinoma Follow-up

Updated: Apr 16, 2015
  • Author: Irfan Maghfoor, MD; Chief Editor: Jules E Harris, MD, FACP, FRCPC  more...
  • Print

Further Outpatient Care

See the list below:

  • Patients with extrapulmonary small cell carcinoma require close monitoring for adverse effects of chemotherapy. Complete blood counts with differential counts should be checked prior to each cycle of chemotherapy to ensure adequate hematologic recovery. Liver and renal function should be monitored to detect toxicity from chemotherapy as well as to assess if adjustment of chemotherapy doses is needed.
  • Response to therapy is monitored by obtaining CT scans after 2 cycles of chemotherapy before chemotherapy is continued.
  • If elevated prior to therapy, serum lactate dehydrogenase is a good marker and should be monitored.


Data linking extrapulmonary small cell carcinoma to tobacco smoking are inconclusive; however, at least one study has reported that most patients with extrapulmonary small cell carcinoma in the study were former or current smokers. Since smoking is implicated as an etiologic agent in several different kinds of malignancies, smoking cessation education and programs with a concerted efforts form health care providers and government agencies are needed.



Tumor lysis syndrome: Tumor lysis can occur rapidly in patients with small cell carcinomas on institution of therapy.



See Mortality/Morbidity.